Clinical Trials Logo

Panniculitis clinical trials

View clinical trials related to Panniculitis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04795869 Withdrawn - Clinical trials for Refractory Angioimmunoblastic T-Cell Lymphoma

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.